Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2023 07:00 ET | Source: Spinogenix, Inc.

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat ALS
September 12, 2023 08:00 ET | Source: Spinogenix, Inc.

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced a second...
July 10, 2023 05:00 ET | Source: Spinogenix, Inc.

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it...
June 07, 2021 07:00 ET | Source: Spinogenix, Inc.

Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis

SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
January 05, 2021 05:00 ET | Source: Spinogenix, Inc.

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced...
May 01, 2018 14:23 ET | Source: Spinogenix, Inc.

Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease

SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a preclinical stage, privately-held pharmaceutical company developing first-in-class drugs to reverse synapse loss and restore...
June 09, 2017 13:10 ET | Source: Medable

Medable Launches Synapse, a Fully Integrated Clinical Care App Platform Using CareKit

PALO ALTO, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- Medable Inc.--the leading app and analytics platform for healthcare--today announced the release of Synapse, the first cloud solution to enable...
August 31, 2011 10:00 ET | Source: Synapse Marketing Solutions

Inc. Magazine Unveils 30th Annual List of America's Fastest-Growing Private Companies - the Inc. 500

NEW YORK, Aug. 31, 2011 (GLOBE NEWSWIRE) -- NEW YORK, August 23, 2011 - Inc. magazine today ranked Synapse Marketing Solutions (Lancaster, PA) No. 396 on its 30th annual Inc. 500, an exclusive ranking...